Literature DB >> 19456991

Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.

Mai Miyakubo1, Kazuto Ito, Takumi Yamamoto, Hiroyuki Takechi, Masaru Ohi, Kazuhiro Suzuki.   

Abstract

OBJECTIVE: To investigate the clinical significance of prostate-specific antigen (PSA)-related markers, including the precursor form of PSA, using the full-range area under the curve of receiver operating characteristics (AUC-ROC), partial AUC-ROC (pAUC-ROC) and multiple logistic regression analyses.
METHODS: Participants consisted of 257 consecutive men (PSA range 4.1-20 ng/mL) undergoing transrectal ultrasonography-guided age-adjusted and prostate volume-adjusted multiple-core prostate biopsy at Gunma University Hospital between January 2003 and May 2005. Sensitivity, specificity, AUC-ROC and pAUC-ROC of the ratio of free PSA to total PSA (free/total PSA), PSA density (PSAD) and PSAD adjusted by transition zone volume, the ratio of [-7/-5] precursor forms of PSA (proPSA) to free PSA (pro/free PSA), the ratio of pro to total PSA and the ratio of pro to free/total PSA (pro/f/t ratio) were investigated. Multiple logistic regression analyses were also carried out to investigate the independency of selected clinical parameters.
RESULTS: According to pAUC-ROC analyses, pro/free PSA and the pro/f/t ratio were the two best PSA-related parameters in terms of maintaining high sensitivity and avoiding unnecessary biopsy. Multiple regression analyses revealed that not only pro/free PSA, but also age, findings on digital rectal examination and PSAD were independent parameters for predicting biopsy outcomes.
CONCLUSION: Pro/free PSA and pro/f/t ratio may be excellent predictive markers for prostate cancer, allowing unnecessary biopsy to be avoided while maintaining high sensitivity at 90% or 95%, in the PSA range 4-20 ng/mL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19456991     DOI: 10.1111/j.1442-2042.2009.02304.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  4 in total

1.  A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.

Authors:  Lori J Sokoll; Martin G Sanda; Ziding Feng; Jacob Kagan; Isaac A Mizrahi; Dennis L Broyles; Alan W Partin; Sudhir Srivastava; Ian M Thompson; John T Wei; Zhen Zhang; Daniel W Chan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

2.  Intrinsic fluorescence of protoporphyrin IX from blood samples can yield information on the growth of prostate tumours.

Authors:  Flávia Rodrigues de Oliveira Silva; Maria Helena Bellini; Vivian Regina Tristão; Nestor Schor; Nilson Dias Vieira; Lilia Coronato Courrol
Journal:  J Fluoresc       Date:  2010-04-24       Impact factor: 2.217

3.  Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range.

Authors:  Kazuto Ito; Mai Miyakubo; Yoshitaka Sekine; Hidekazu Koike; Hiroshi Matsui; Yasuhiro Shibata; Kazuhiro Suzuki
Journal:  World J Urol       Date:  2012-08-18       Impact factor: 4.226

Review 4.  PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.

Authors:  Sema Nur Ayyıldız; Ali Ayyıldız
Journal:  Turk J Urol       Date:  2014-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.